| Autor: |
M.L. Martínez-Ginés, J.M. García-Domínguez, J.P. Cuello, V. Meca-Lallana, C. Aguirre, L. Costa-Frossard, E. Monreal, S. Sainz de la Maza, P. Salgado-Cámara, A. Labiano-Fontcuberta, L. Fernández-Cabredo, Y. Aladro-Benito, L.B. Canelo, O.Sánchez-del Valle, M.R. Blasco, J. Sabin-Muñoz, A.B. Caminero-Rodríguez, J. Gracia-Gil, E. Fernandez-Diaz, A. Mendoza-Rodríguez, M. Gómez-Moreno, A. Orviz-García, I. Moreno-Torres, L.I. Casanova-Peño, A. Lozano-Ros |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Neurology Perspectives, Vol 3, Iss 4, Pp 100133- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0496 |
| DOI: |
10.1016/j.neurop.2023.100133 |
| Popis: |
Introduction and objective: Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods: Non-interventional, retrospective study at 15 sites in the Autonomous Region of Madrid and nearby regions. Effectiveness (relapses, EDSS, gadolinium-enhancing T1 lesions and new/enlarged T2-weighted lesions), safety (adverse events), and reasons for discontinuation during the 24 months after teriflunomide initiation were reported. Results: A total of 776 patients were included (mean [SD] age was 43.3 (9.8) years; 69.3% were female). Two-thirds (67.7%) of patients had received a prior treatment, with beta-interferons or glatiramer acetate (BRACE) as the most frequent (93.5%) treatment. After 24 months, teriflunomide significantly reduced the annualized relapse rate (ARR) by 72% (mean [95% confidence interval] 0.12 [0.10, 0.14] vs 0.43 [0.40, 0.47] at baseline; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
